Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

PhRMA Sues To Block HHS Drug Importation Rule Citing Security, Safety, First Amendment Concerns

Executive Summary

Complaint lists host of problems with implementation of the rule that allows states to sponsor programs to import certain prescription drugs from Canada; at least six states have enacted legislation to sponsor these programs.

You may also be interested in...



FDA Authorizes Florida Importation Plan, But No Drugs Cleared For Landing

The US FDA's authorization of the first ever Section 804 importation program is a notable political move, but hurdles remain before the state can import drugs and savings are expected to be minimal.

FDA To Issue Decision On Florida’s Drug Importation Proposal By October

Florida was the first of four states to submit proposals for importation of prescription drugs from Canada. PhRMA recently filed a citizen petition opposing Colorado’s proposal, which notes hurdles it is facing. Infographic compares state proposals and the drugs they plan to import.

Importation, Pay-For-Delay Reform Backed By Biden Order; March-In Rights For Pricing Suggested

The policies have long been Democratic priorities, but of the three, the order’s implicit support for march-in rights might lead to the biggest change.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS143348

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel